1207284-87-4

Usage

Uses

Used in Organic Synthesis:
Phenyl 3-fluoro-6-hydroxy-2-methyl-5-nitrobenzoate is utilized as a key intermediate in the synthesis of various organic compounds. Its unique functional groups enable it to participate in a range of chemical reactions, facilitating the creation of new molecules with potential applications in various industries.
Used in Pharmaceutical Development:
In the pharmaceutical industry, phenyl 3-fluoro-6-hydroxy-2-methyl-5-nitrobenzoate is employed as a building block for the development of new drugs. Its structural diversity and reactivity make it a promising candidate for the synthesis of novel therapeutic agents, potentially leading to the discovery of new treatments for various diseases and conditions.
Used in Agrochemical Production:
Phenyl 3-fluoro-6-hydroxy-2-methyl-5-nitrobenzoate is also used in the agrochemical sector as a starting material for the synthesis of pesticides and other crop protection products. Its chemical properties allow for the creation of compounds that can effectively control pests and diseases in agriculture, contributing to increased crop yields and food security.

Upstream product

• 1207283-54-2 phenyl 3-fluoro-6-methoxy-2-methylbenzoate 
• 220901-72-4 3-fluoro-6-methoxy-2-methylbenzoic acid 
• 394-04-7 5-fluoro-2-methoxybenzoic acid 
• 1207283-55-3 phenyl 3-fluoro-6-hydroxy-2-methylbenzoate 

Downstream Products

• 1207284-88-5 phenyl 2-(benzyloxy)-5-fluoro-6-methyl-3-nitrobenzoate 
• 1207284-89-6 phenyl 3-amino-2-(benzyloxy)-5-fluoro-6-methylbenzoate 
• 1254339-80-4 C₃₁H₃₄FNO₇ 
• 1254339-82-6 C₂₇H₂₆FNO₆ 
• 1335557-66-8 C₃₃H₄₁FN₂O₆ 
• 1335557-67-9 C₃₆H₄₅FN₂O₆ 
• 1335557-68-0 C₃₆H₄₄ClFN₂O₅ 
• 1335557-69-1 C₃₆H₄₃FN₂O₅ 
• 1335557-70-4 C₅₆H₇₁FN₄O₉Si 
• 1335557-71-5 C₄₅H₄₉FN₄O₇ 
• 1335557-72-6 C₅₃H₆₇FN₄O₉Si 
• 1335557-73-7 C₅₄H₆₉FN₄O₉Si 
• 1253799-29-9 phenyl 2-(benzyloxy)-3-(dibenzylamino)-5-fluoro-6-methylbenzoate 
• 1207284-90-9 phenyl 2-(benzyloxy)-3-[bis(prop-2-en-1-yl)amino]-5-fluoro-6-methylbenzoate 

Relevant academic research and scientific papers

Tetracycline compounds

The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy

Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents.

POLYCYCLIC TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I) and its therapeutic use.

C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS

The present invention is directed to a compound represented by Structural Formula (A): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (A) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (A) and its therapeutic use.

SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The recent development of a modular synthesis of tetracycline analogs through a chiral enone intermediate has allowed for the efficient synthesis of novel tetracycline analogs never prepared before. The present invention provides more efficient routes for preparing the enone intermediate and allows for substituents at positions 4a, 5, 5a, and 12a of the tetracycline ring system.